These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20411161)

  • 21. Radiation Safety Precautions in (131)I Therapy of Graves' Disease Based on Actual Biokinetic Measurements.
    Liu B; Tian R; Peng W; He Y; Huang R; Kuang A
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2934-41. PubMed ID: 26046966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lithium as an adjunct to radioiodine therapy in Graves' disease for prolonging the intrathyroidal effective half-life of radioiodine. Useful or not?
    Dunkelmann S; Künstner H; Nabavi E; Eberlein U; Groth P; Schümichen C
    Nuklearmedizin; 2006; 45(5):213-8; quiz N51-2. PubMed ID: 17043732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Concept and validation of a simple model of the intrathyroidal iodine kinetics].
    Rink T; Bormuth FJ; Braun S; Zimny M; Schroth HJ
    Nuklearmedizin; 2004 Feb; 43(1):21-5. PubMed ID: 14978537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
    Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
    Urbannek V; Voth E; Moka D; Schicha H
    Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radioiodine therapy and thyrostatic drugs and iodine.
    Moka D; Dietlein M; Schicha H
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S486-91. PubMed ID: 12192550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Errors in the absorbed and the administered
    Chen Y; Huang J; Wang Y; Xie S; He F
    Hell J Nucl Med; 2017; 20(3):217-221. PubMed ID: 29177256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Orbital flourine-18-fluorodeoxyglucose positron emission tomography in patients with Graves' disease for evaluation of active inflammation.
    Uslu-Beşli L; Kabasakal L; Sağer S; Cicik E; Asa S; Sönmezoğlu K
    Nucl Med Commun; 2017 Nov; 38(11):964-970. PubMed ID: 28863123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iodine-131 uptake and turnover rate vary over short intervals in Graves' disease.
    Van Isselt JW; de Klerk JM; Koppeschaar HP; Van Rijk PP
    Nucl Med Commun; 2000 Jul; 21(7):609-16. PubMed ID: 10994662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Paradoxical effect of radioiodine therapy in functional thyroid autonomy and mild immunothyropathy].
    Dunkelmann S; Rudolph F; Prillwitz A; Groth P; Schümichen C
    Nuklearmedizin; 1998 Jan; 37(1):23-9. PubMed ID: 9467166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A NTCP approach for estimating the outcome in radioiodine treatment of hyperthyroidism.
    Strigari L; Sciuto R; Benassi M; Bergomi S; Nocentini S; Maini CL
    Med Phys; 2008 Sep; 35(9):3903-10. PubMed ID: 18841841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Possibility of limiting the un-justified irradiation in (131)I therapy of Graves' disease: a thyroid mass-reduction based method for the optimum activity calculation.
    Traino AC; Grosso M; Mariani G
    Phys Med; 2010 Apr; 26(2):71-9. PubMed ID: 19800827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radioiodine associated de novo Graves' opthalmopathy in an Asian cohort.
    Tay WL; Tong AKT; Hui KYD; Tang YLC; Chng CL
    Hell J Nucl Med; 2017; 20(3):227-231. PubMed ID: 29177260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of iodine application during radioiodine therapy in patients with impending therapy failure].
    Urbannek V; Schmidt M; Moka D; Hillger HW; Voth E; Wellner U; Schicha H
    Nuklearmedizin; 2000; 39(4):108-12. PubMed ID: 10919161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of prior carbimazole on the outcome of radioiodine therapy in pediatric and adolescent Graves' disease.
    Ballal S; Soundararajan R; Singh H; Garg A; Chopra S; Bal C
    Nucl Med Commun; 2015 Jun; 36(6):566-72. PubMed ID: 25757198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance].
    Krohn T; Meyer PT; Ocklenburg C; Knollmann D; Nowak B; Schaefer WM
    Nuklearmedizin; 2008; 47(6):248-54. PubMed ID: 19057798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experience with ambulatory radioiodine therapy of hyperthyroidism].
    Róka R; Séra T; Valkusz Z; Julesz J; Csernay L; Pávics L
    Orv Hetil; 1999 Jun; 140(23):1291-5. PubMed ID: 10412264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized comparison of radioiodine doses in Graves' hyperthyroidism.
    Leslie WD; Ward L; Salamon EA; Ludwig S; Rowe RC; Cowden EA
    J Clin Endocrinol Metab; 2003 Mar; 88(3):978-83. PubMed ID: 12629071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of short-term interruption of antithyroid drugs on the outcome of radioiodine therapy of Graves' disease: results of a prospective study.
    Eschmann SM; Thelen MH; Dittmann H; Bares R
    Exp Clin Endocrinol Diabetes; 2006 May; 114(5):222-6. PubMed ID: 16804795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.